Amarin 将来の成長
Future 基準チェック /36
Amarinは、76%と0.7%でそれぞれ年率76%で利益と収益が成長すると予測される一方、EPSはgrowで105.7%年率。
主要情報
76.0%
収益成長率
105.74%
EPS成長率
| Biotechs 収益成長 | 25.2% |
| 収益成長率 | 0.7% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 29 Apr 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 22
AMRN: Guideline Endorsements Will Still Translate Into Weak Future Earnings
Analysts have kept their $12.50 price target on Amarin unchanged. They cited only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially alter their valuation view.ナラティブの更新 • Jun 05
AMRN: Guideline Inclusion Will Still Lead To Persistent Revenue Pressure
Analysts kept their $12.50 price target for Amarin unchanged, citing only very small model tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially affect their overall valuation view. What's in the News Shareholders are scheduled to vote at the May 13, 2026 Annual General Meeting on adopting amended and restated articles of association, which would allow Amarin to send electronic notices of future Annual General Meetings via a website if approved.ナラティブの更新 • May 21
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Analysts have lifted their price target on Amarin stock by $0.50 to $12.50, citing updated assumptions around slightly lower expected revenue declines, a higher projected profit margin, a modestly reduced discount rate, and a lower future P/E multiple as the key drivers of the change. Analyst Commentary Recent commentary around Amarin’s updated price target highlights a mix of optimism on execution and ongoing caution on longer term growth and valuation risk.ナラティブの更新 • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.ナラティブの更新 • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.ナラティブの更新 • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.ナラティブの更新 • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.ナラティブの更新 • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.ナラティブの更新 • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.ナラティブの更新 • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.ナラティブの更新 • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).分析記事 • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...ナラティブの更新 • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.ナラティブの更新 • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.分析記事 • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...分析記事 • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...分析記事 • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
新しいナラティブ • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.分析記事 • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...分析記事 • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...分析記事 • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking Alpha分析記事 • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking Alpha分析記事 • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...分析記事 • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 188 | 27 | N/A | N/A | 2 |
| 12/31/2027 | 193 | 22 | N/A | N/A | 2 |
| 12/31/2026 | 182 | -15 | N/A | N/A | 2 |
| 3/31/2026 | 217 | -34 | 26 | 26 | N/A |
| 12/31/2025 | 214 | -39 | 7 | 7 | N/A |
| 9/30/2025 | 227 | -86 | -22 | -22 | N/A |
| 6/30/2025 | 219 | -104 | -12 | -12 | N/A |
| 3/31/2025 | 214 | -88 | -31 | -31 | N/A |
| 12/31/2024 | 229 | -82 | -31 | -31 | N/A |
| 9/30/2024 | 241 | -39 | -19 | -18 | N/A |
| 6/30/2024 | 265 | -34 | -9 | -9 | N/A |
| 3/31/2024 | 277 | -53 | 1 | 1 | N/A |
| 12/31/2023 | 307 | -59 | 6 | 7 | N/A |
| 9/30/2023 | 322 | -52 | 8 | 9 | N/A |
| 6/30/2023 | 346 | -38 | -17 | -16 | N/A |
| 3/31/2023 | 361 | -91 | -89 | -88 | N/A |
| 12/31/2022 | 369 | -106 | -181 | -180 | N/A |
| 9/30/2022 | 423 | -92 | -210 | -210 | N/A |
| 6/30/2022 | 476 | -100 | -196 | -196 | N/A |
| 3/31/2022 | 536 | -22 | -147 | -147 | N/A |
| 12/31/2021 | 583 | 8 | -67 | -67 | N/A |
| 9/30/2021 | 606 | -2 | -77 | -77 | N/A |
| 6/30/2021 | 620 | 4 | -61 | -61 | N/A |
| 3/31/2021 | 601 | 1 | -45 | -45 | N/A |
| 12/31/2020 | 614 | -18 | -22 | -22 | N/A |
| 9/30/2020 | 590 | -16 | 7 | 8 | N/A |
| 6/30/2020 | 546 | -13 | 17 | 19 | N/A |
| 3/31/2020 | 511 | -19 | 30 | 33 | N/A |
| 12/31/2019 | 430 | -23 | N/A | -9 | N/A |
| 9/30/2019 | 364 | -63 | N/A | -33 | N/A |
| 6/30/2019 | 307 | -84 | N/A | -83 | N/A |
| 3/31/2019 | 259 | -117 | N/A | -123 | N/A |
| 12/31/2018 | 229 | -116 | N/A | -95 | N/A |
| 9/30/2018 | 206 | -105 | N/A | -65 | N/A |
| 6/30/2018 | 198 | -92 | N/A | -43 | N/A |
| 3/31/2018 | 190 | -71 | N/A | -29 | N/A |
| 12/31/2017 | 181 | -68 | N/A | -33 | N/A |
| 9/30/2017 | 166 | -73 | N/A | -50 | N/A |
| 6/30/2017 | 151 | -78 | N/A | -62 | N/A |
| 3/31/2017 | 139 | -78 | N/A | -61 | N/A |
| 12/31/2016 | 130 | -86 | N/A | -72 | N/A |
| 9/30/2016 | 118 | -81 | N/A | -76 | N/A |
| 6/30/2016 | 107 | -97 | N/A | -80 | N/A |
| 3/31/2016 | 91 | -147 | N/A | -96 | N/A |
| 12/31/2015 | 82 | -149 | N/A | -84 | N/A |
| 9/30/2015 | 72 | -147 | N/A | -74 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: AMRNは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。
収益対市場: AMRN今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: AMRN今後 3 年以内に収益を上げることが予想されます。
収益対市場: AMRNの収益 ( 0.7% ) US市場 ( 12.8% ) よりも低い成長が予測されています。
高い収益成長: AMRNの収益 ( 0.7% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: AMRNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/01 02:54 |
| 終値 | 2026/07/01 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Amarin Corporation plc 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19
| アナリスト | 機関 |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |